Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field...
Johnson & Johnson rose 1.9% to $259.27 during regular trading, extending gains in post-market sessions, propelled by better-than-expected Q2 results and major pipeline achievements. Q2 revenue reached $25.31 billion, up 6.6% year-over-year and exceeding consensus. The medical devices segment achieved a pivotal win: the OTTAVA soft-tissue surgical robot earned FDA De Novo clearance, the highest approval tier for innovative US medical devices, marking strategic progress in surgical robotics. On pharma, the TECVAYLI+TALVEY combination demonstrated an 89% reduction in disease progression or death risk in multiple myeloma trials. Legal headwinds eased as a US judge cast doubt on talc-cancer litigation involving roughly 69,000 cases. Valuation-wise, the stock has rallied 25% year-to-date and trades 3.77% below its 52-week high of $269.43, suggesting lingering upside. However, with a PE multiple at 29.67x and valuations elevated, sustained earnings growth remains key to supporting further appreciation.
J&J climbed 2% to $255.63 today, primarily driven by FDA approval of its Ottava robotic surgery system, marking a major milestone for the company's medical technology division. Concurrently, a U.S. judge cast doubt on 69,000 talc-related cancer cases, significantly reducing litigation risk exposure. Intraday trading was robust, with the stock rising from $251.45 to $256.21, reflecting strong buying interest. The stock now trades 5.12% below its 52-week high of $269.43 but sits well above both its 20-day moving average of $254.64 and 60-day moving average of $237.92. Q2 earnings showed revenue growth of 6.6% year-over-year to $25.31 billion with a net margin of 21.86%, though earnings per share declined 0.96% on a yearly basis. Recent insider share disposals and an elevated P/E ratio of 29.25 suggest some market caution regarding current valuations.
Johnson & Johnson advanced 0.67% to $250.50 on July 21, with an intraday peak of $251.31 followed by pullback, illustrating the balance between buyers and sellers. Q2 earnings supported upside momentum: revenue of $25.31 billion rose 6.6% year-over-year, Guggenheim maintained its buy rating, and Jim Cramer highlighted market mispricing of the stock. However, EPS of $2.27 declined 0.96% year-over-year despite recovery from Q1's 52.86% collapse, while insider selling—particularly EVP Vanessa Broadhurst's disposal of 23,054 shares for $5.79 million—signaled management caution on valuation. Positionally, J&J has gained 20.86% year-to-date but remains 7% below its 52-week high of $269.43 (July 7), with a P/E multiple of 28.68 reflecting elevated valuation levels; the stock trades below its 20-day moving average yet above its 60-day average.
Johnson & Johnson declined 1.7% to $248.82 today, primarily due to profit-taking following its Q2 earnings report. Despite revenue growth of 6.6% year-over-year to $25.31 billion, earnings per share fell 0.96% and net income of $5.534 billion was essentially flat, revealing underlying margin pressure with a net profit margin of 21.86%. The stock traded from an open of $252.01 down to a session low of $248.63, recovering slightly to $249.47 in post-market trading. Positionally, JNJ has gained roughly 20% year-to-date and trades only 7.65% below its 52-week high of $269.43, representing near all-time highs, with the stock well above its 60-day moving average of $237.12. Analyst sentiment remains constructive, with Guggenheim maintaining a buy rating and citing momentum in immunology into 2027. However, the lack of earnings growth presents a near-term headwind, with investors watching for signs of margin recovery.
Johnson & Johnson shares edged up 1.23% to $253.04 today, supported by upbeat Q2 earnings and recent analyst endorsement. The company's Q2 revenue climbed to $25.31 billion with 6.6% year-over-year growth, driven by strong performance in innovative medicines while the medical devices segment disappointed relative to expectations; net profit remained essentially flat year-over-year at $5.53 billion with a solid 21.9% net margin. Guggenheim maintained a buy rating on the stock. From a technical and valuation standpoint, JNJ has gained 22.04% year-to-date and currently sits just 6.08% below its 52-week high of $269.43, above both the 20-day and 60-day moving averages, pointing to underlying strength. However, with a P/E ratio near 30x, valuations reflect elevated levels as the market has already priced in growth expectations, potentially constraining further near-term upside.
Johnson & Johnson | 10-Q: FY2026 Q2 Revenue Beats Estimate at USD 25.31 B
J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.
J&J names C1DO1, Curium Life Tech, iQ Surgical as Polyphonic AI Fund for Surgery cohort at SRS meeting
J&J Says TECVAYLI+TALVEY Cuts Risk Of Disease Progression Or Death By 89% In Multiple Myeloma Trial
Johnson & Johnson posts press release on MonumenTAL-6 multiple myeloma trial results
Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today
This is my humble U.S. stock holdings, mainly made up of defensive income stocks. I know my portfolio is still very much a newbie’s collection, but I’m learning as I go. I’d really appreciate any advice, comments, or suggestions on how I can improve my holdings and build a stronger portfolio over time.
